BeiGene | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

⟵ Back to Search Results

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Beigene Study ID

AdvanTIG-302

ClinicalTrials.gov ID

NCT04746924

EudraCT Number

2020-004985-21

China Drug Trials ID

CTR20211476/CTR20211464

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents